Tumour suppressor genes in prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Tumour suppressor gene inactivation is crucial for human neoplasia development.
• Genes such as Rb and CDKN2 are inactivated in various tumors, including advanced prostate cancer, suggesting a shared pathway.
• p53 mutations and altered cell adhesion genes (e.g., E-cadherin) are observed in advanced prostate carcinomas, correlating with poor outcomes.

Purpose of the Study:

• To review the role of tumour suppressor genes in prostate cancer progression.
• To highlight the genetic alterations associated with advanced-stage and metastatic prostate cancer.
• To underscore the need for understanding early genetic events in prostatic neoplasia.

Main Methods:

• Literature review and analysis of genetic alterations in prostate cancer.
• Examination of tumour suppressor gene status (inactivation, mutation, downregulation).
• Correlation of genetic events with clinical outcomes and metastatic potential.

Main Results:

• Rb and CDKN2 tumour suppressor genes are frequently inactivated in prostate cancer, functioning within the same pathway.
• p53 mutations occur in a subset of advanced prostate carcinomas.
• Inactivation or downregulation of cell adhesion genes like E-cadherin is linked to metastasis and poor prognosis in advanced prostate cancer.

Conclusions:

• Tumour suppressor gene inactivation is a hallmark of prostate cancer progression.
• Alterations in Rb, CDKN2, p53, and cell adhesion genes contribute to advanced disease and metastasis.
• Early genetic events, potentially involving undiscovered tumour suppressor genes, are critical for prostate cancer initiation.